Videos

New data show that while men are diagnosed with breast cancer at a mere fraction of the rate of women, they tend to have more advanced disease at the time of diagnosis.

The combination of anastrozole and fulvestrant improved survival when used as first-line therapy in postmenopausal women with metastatic HR-positive breast cancer compared with anastrozole alone.

Patients with metastatic breast cancer who were treated with eribulin mesylate were less likely to experience peripheral neuropathy.

The developing theme is that bisphosphonates are most effective in postmenopausal patients with HR-positive breast cancer.

While pertuzumab is moving ahead in the FDA approval process, an additional indication for denosumab might be halted.

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the Stratification of Clinical Trials

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Describes Retesting Recurrent Breast Cancer

Dr. Jose Baselga, from Massachusetts General Hospital, Describes the Basis Behind the BOLERO-2 Trial

Upfront zoledronic acid is superior to delayed use in postmenopausal women with early breast cancer who are being treated with the aromatase inhibitor letrozole.

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses Targeting the mTOR Pathway

Dr. Kevin Fox, from Abramson Cancer Center, Discusses Genomic Testing in Breast Cancer

Dr. Harold Burstein, from the Dana-Farber Cancer Institute, Discusses Pathological Complete Response

Dr. Linda Vahdat, from New York-Presbyterian Hospital, Discusses the Side Effects of Halaven

Two new studies suggest that dual inhibition of HER2 might serve as a better approach to treating patients with HER2-positive breast cancer.

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Discusses Obesity as a Predictive Marker

A group of pharmacologic inhibitors of the enzyme poly ADP ribose polymerase, are gaining ground as a potential strategy for treating triple-negative breast cancer.

Dr. Debu Tripathy, from USC Norris Comprehensive Cancer Center, on the Miami Breast Cancer Conference

A phase II study of NKTR 102 suggest that this agent will find a role in the treatment of patients with heavily pretreated metastatic breast cancer whose disease is progressing.

Dr. Clifford Hudis, from Memorial Sloan-Kettering Cancer Center, Discusses Axillary Lymph Node Status

Beth Baughman DuPree, MD, FACS, discussed the latest in breast cancer care at the 3rd Annual NCONN Conference.

Patients with hormone receptor-positive metastatic breast cancer (MBC) frequently respond to multiple lines of endocrine therapy but, unfortunately, resistance eventually develops.

One of a small group of scientists who had a hand in developing Herceptin (trastuzumab) for the treatment of breast cancer, Dr. Debu Tripathy's current work is focused on understanding why some patients are resistant to the drug, and how to create more effective therapies for them.

The approval of trastuzumab, targeted directly to the human epidermal growth factor receptor (HER2)-positive, was a major advance in extending the lives of women with HER2-positive breast cancer.

Dr. Linda Vahdat, from the New York-Presbyterian Hospital, Compares Halaven and Ixempra Neuropathy

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Florida, Discusses the B-34 Clodronate Study

Recently reported and truly impressive clinical trial data have revealed the relevance of administering antineoplastic agents specifically and prospectively targeted to molecular abnormalities.

A subanalysis of the AZURE study found that postmenopausal women had a disease-free survival advantage from the addition of zoledronic acid to their therapy.

Dr. Jose Baselga from Massachusetts General Hospital Describes the Advantages of Dual Blockade

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Discusses the BOLERO-2 Everolimus Trial

A study of bevacizumab in women with HER2-positive metastatic breast cancer demonstrated that combining the drug with standard therapy improves PFS.